ragifilimab

{
  "id": "MLC-T-ONC-016352",
  "term": "ragifilimab",
  "field": "Oncology and biomedicine",
  "definition": "An anti-human glucocorticoid-induced tumor necrosis factor receptor (tumor necrosis factor superfamily, member 18; TNFRSF18; GITR; CD357) agonistic humanized monoclonal antibody, with potential immune checkpoint modulating activity. Ragifilimab binds to and activates GITRs found on multiple types of T cells. This stimulates the immune system, induces both the activation and proliferation of tumor-antigen-specific T-effector cells (Teff), and suppresses the function of activated T-regulatory cells (Tregs). This leads to tumor cell eradication. GITR, a member of the TNF receptor superfamily and T-cell receptor co-stimulator, is expressed on the surface of multiple immune cell types, including Tregs, Teffs, B cells, and natural killer (NK) cells. Inappropriately activated Tregs suppress Teffs and suppress T-cell receptor (TCR) signaling.",
  "synonyms": [
    "anti-GITR agonistic monoclonal antibody INCAGN01876"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/ragifilimab/"
}